New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
09:12 EDTOWW, ORCL, KBH, PSUN, HZNP, EXAS, RENN, RBCNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: KB Home (KBH), up 7%...Pacific Sunwear (PSUN), up 7%. ALSO HIGHER: Horizon Pharma (HZNP), up 23% after deal to acquire Ireland's Vidara Therapeutics through reverse merger... Exact Sciences (EXAS), up 6.5% after a clinical trial of its Cologuard test, which it co-developed with the Mayo Clinic, showed "unprecedented" rates of precancer and cancer detection by a noninvasive test... DOWN AFTER EARNINGS: Oracle (ORCL), down 3.3%... Renren (RENN), down 7%. ALSO LOWER: Orbitz (OWW), down 5.4% after Goldman downgraded shares to Sell from Neutral... Rubicon (RBCN), down 6% after 2.5M share spot secondary offering priced at $13.00.
News For OWW;ORCL;KBH;PSUN;HZNP;EXAS;RENN;RBCN From The Last 14 Days
Check below for free stories on OWW;ORCL;KBH;PSUN;HZNP;EXAS;RENN;RBCN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 20, 2014
11:47 EDTEXASOptions with increasing implied volatilit
Subscribe for More Information
August 18, 2014
08:05 EDTEXASExact Sciences risk/reward positive, says Canaccord
Canaccord said the scenario analysis of upcoming catalysts suggests positive risk/reward for the shares of Exact Sciences. The firm cited its potential for reimbursement approvals form both the CMS and commercial payers. Shares of Exact Sciences remain Buy rated with a $21 price target.
August 15, 2014
08:11 EDTORCLOracle checks showing signs of improvement, says FBR Capital
Subscribe for More Information
August 14, 2014
18:28 EDTORCLCourt finds Rimini Street infringed Oracle copyrights, stole IP
On August 14, the U.S. District Court in Las Vegas entered an order granting Oracle's motion for partial summary judgment in its case against Rimini Street, and its CEO, Seth Ravin. Oracle moved for summary judgment on Rimini's counterclaims for defamation and unfair competition. In those counterclaims, Rimini challenged Oracle's public statements that Rimini had engaged in massive theft of Oracle's intellectual property. The Court dismissed those counterclaims finding that Oracle's statements "that Rimini had engaged in 'massive theft' of Oracle's intellectual property are true." The Court explained that "It is undisputed that Rimini engaged in theft of Oracle's intellectual property." The Court also found that Rimini Street infringed Oracle's copyrights. In February, the Court found that Rimini Street infringed Oracle's PeopleSoft copyrights and that Oracle had proved prima facie copyright infringement as to its JD Edwards and Siebel copyrights. The Court ruled that Rimini Street also infringed Oracle Database copyrights. The Court found that Rimini Street had downloaded 25 copies of Oracle's Database software and possessed over 200 copies of this software even though Rimini's downloading, possession, and use of this software all was unlicensed. The Court ordered the parties to submit a pre-trial order within sixty days.
August 13, 2014
16:03 EDTORCLOracle extends tender offer for MICROS to September 2
Subscribe for More Information
08:50 EDTEXASExact Sciences CMS approval expected by early September, says Canaccord
Canaccord met with Exact Sciences management and came away confident in the CMS' preliminary reimbursement amount, which the firm expects by early September. Canaccord also noted checks into the company's call center indicated strong interest in Cologuard and it expects targeted digital advertising to raise awareness of its product. The firm raised its price target on the stock to $21 from $20 and keeps its Buy rating on the shares.
07:32 EDTHZNPHorizon Pharma, POZEN announce USPTO Notice of Allowance for VIMOVO
Subscribe for More Information
August 12, 2014
09:35 EDTEXASActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GOOG C TSL EXAS BAC DNDN JNJ TSLA
09:21 EDTEXASOn The Fly: Pre-market Movers
Subscribe for More Information
07:24 EDTEXASExact Sciences FDA approval priced into shares, says Maxim
Subscribe for More Information
07:14 EDTEXASExact Sciences announces FDA approved Cologuard
Subscribe for More Information
August 11, 2014
16:24 EDTEXASFDA announces approval of Exact Sciences colorectal screening test
The FDA said it approved Cologuard, the first stool-based colorectal screening test that detects the presence of red blood cells and DNA mutations that may indicate the presence of certain kinds of abnormal growths that may be cancers such as colon cancer or precursors to cancer. The FDA added that the Centers for Medicare & Medicaid Services proposes to cover the Cologuard test once every three years for Medicare beneficiaries who meet certain criteria. Cologuard is manufactured by Exact Sciences. Reference Link
August 9, 2014
16:26 EDTORCLOracle sues Oregon over dispute with state's health-insurance exchange, WSJ says
Subscribe for More Information
August 8, 2014
10:34 EDTHZNP, OWWOptions with decreasing implied volatility
Subscribe for More Information
10:00 EDTRBCNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:30 EDTRBCNRubicon price target cut to $10 from $17 at DA Davidson
DA Davidson cut its price target on Rubicon after the company reported in-line results but provided Q2 guidance that the firm views as lackluster. The firm expects the company's business to eventually rebound and keeps a Buy rating.
07:51 EDTRBCNRubicon downgraded to Hold at Canaccord
Subscribe for More Information
07:35 EDTHZNPHorizon announces S-4 registration statement for Vidara declared effective
Subscribe for More Information
06:48 EDTRBCNRubicon downgraded to Hold from Buy at Canaccord
Subscribe for More Information
06:34 EDTRBCNRubicon downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use